Lighting the way to host-directed immunotherapeutics

Developing broad-spectrum, host-directed antiviral therapeutics can be adapted to combat emerging viruses. In this issue of Cell Chemical Biology, Maarifi and colleagues implement a Nano luciferase reporter-based protein complementation assay to screen for small molecules and identify Gilteritinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: van Tol, Sarah, Hage, Adam, Rajsbaum, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548442/
https://www.ncbi.nlm.nih.gov/pubmed/35868235
http://dx.doi.org/10.1016/j.chembiol.2022.06.009
_version_ 1784805436542681088
author van Tol, Sarah
Hage, Adam
Rajsbaum, Ricardo
author_facet van Tol, Sarah
Hage, Adam
Rajsbaum, Ricardo
author_sort van Tol, Sarah
collection PubMed
description Developing broad-spectrum, host-directed antiviral therapeutics can be adapted to combat emerging viruses. In this issue of Cell Chemical Biology, Maarifi and colleagues implement a Nano luciferase reporter-based protein complementation assay to screen for small molecules and identify Gilteritinib, which enhances interferon induction and antagonizes virus replication.
format Online
Article
Text
id pubmed-9548442
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-95484422022-10-11 Lighting the way to host-directed immunotherapeutics van Tol, Sarah Hage, Adam Rajsbaum, Ricardo Cell Chem Biol Preview Developing broad-spectrum, host-directed antiviral therapeutics can be adapted to combat emerging viruses. In this issue of Cell Chemical Biology, Maarifi and colleagues implement a Nano luciferase reporter-based protein complementation assay to screen for small molecules and identify Gilteritinib, which enhances interferon induction and antagonizes virus replication. Elsevier Ltd. 2022-07-21 2022-07-21 /pmc/articles/PMC9548442/ /pubmed/35868235 http://dx.doi.org/10.1016/j.chembiol.2022.06.009 Text en © 2022 Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Preview
van Tol, Sarah
Hage, Adam
Rajsbaum, Ricardo
Lighting the way to host-directed immunotherapeutics
title Lighting the way to host-directed immunotherapeutics
title_full Lighting the way to host-directed immunotherapeutics
title_fullStr Lighting the way to host-directed immunotherapeutics
title_full_unstemmed Lighting the way to host-directed immunotherapeutics
title_short Lighting the way to host-directed immunotherapeutics
title_sort lighting the way to host-directed immunotherapeutics
topic Preview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548442/
https://www.ncbi.nlm.nih.gov/pubmed/35868235
http://dx.doi.org/10.1016/j.chembiol.2022.06.009
work_keys_str_mv AT vantolsarah lightingthewaytohostdirectedimmunotherapeutics
AT hageadam lightingthewaytohostdirectedimmunotherapeutics
AT rajsbaumricardo lightingthewaytohostdirectedimmunotherapeutics

Ejemplares similares